Maravai Lifesciences Holdings (MRVI) Cash & Equivalents (2022 - 2026)

Maravai Lifesciences Holdings' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $165.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 41.79% year-over-year to $165.9 million in Q1 2026; TTM through Mar 2026 was $165.9 million, a 41.79% decrease from a year earlier, with the FY2025 full-year figure at $216.9 million, down 32.73% from the prior year.
• Cash & Equivalents retreated to $165.9 million in Q1 2026 per MRVI's latest filing, from $216.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $632.1 million in Q4 2022 and bottomed at $165.9 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $561.7 million (2024), against an average of $429.5 million.
• Across the five-year window, Cash & Equivalents dropped 0.25% in 2024 and slumped 57.87% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $632.1 million in 2022, then slipped by 9.04% to $575.0 million in 2023, then tumbled by 43.93% to $322.4 million in 2024, then slumped by 32.73% to $216.9 million in 2025, then declined by 23.5% to $165.9 million in 2026.
• Per Business Quant, the three latest MRVI Cash & Equivalents figures stand at $165.9 million (Q1 2026), $216.9 million (Q4 2025), and $243.6 million (Q3 2025).